Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.
暂无分享,去创建一个
P. LoRusso | J. Sebolt-Leopold | A. Adjei | R. Herrera | S. Gadgeel | M. Meyer | J. Reid | Keri Van Becelaere | M. Varterasian | Peggy Asbury | D. Mitchell | L. Hanson | P. Deluca | L. Bruzek | J. Piens
[1] P. LoRusso,et al. A phase 1–2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer , 2005 .
[2] J. Sebolt-Leopold,et al. Targeting the mitogen-activated protein kinase cascade to treat cancer , 2004, Nature Reviews Cancer.
[3] J. Hecht,et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. Warmus,et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition , 2004, Nature Structural &Molecular Biology.
[5] J. Sebolt-Leopold,et al. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). , 2003, Seminars in oncology.
[6] K. Smalley,et al. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? , 2003, International journal of cancer.
[7] Roy S Herbst,et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] A. Adjei,et al. Novel pharmacological agents in clinical development for solid tumours , 2001, Expert opinion on investigational drugs.
[9] E K Rowinsky,et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J. Sebolt-Leopold. Development of anticancer drugs targeting the MAP kinase pathway , 2000, Oncogene.
[11] Alan R. Saltiel,et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo , 1999, Nature Medicine.
[12] Takashi Tsuruo,et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors , 1999, Oncogene.
[13] M. Ratain. Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] N. Ahn,et al. Transformation of mammalian cells by constitutively active MAP kinase kinase. , 1994, Science.
[15] C. Marshall,et al. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells , 1994, Cell.
[16] J. Pouysségur,et al. Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[17] Jonathan A. Cooper,et al. Purification and characterization of mitogen-activated protein kinase activator(s) from epidermal growth factor-stimulated A431 cells. , 1992, The Journal of biological chemistry.
[18] J. Maller,et al. Requirement for integration of signals from two distinct phosphorylation pathways for activation of MAP kinase , 1990, Nature.
[19] I M Buzzard,et al. Sources of data for developing and maintaining a nutrient database. , 1988, Journal of the American Dietetic Association.
[20] R K Craig,et al. Methods in molecular medicine. , 1987, British medical journal.